MARATTO

article · The Lancet Infectious Diseases

Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial

2026Open accessArba Minch University

In plain language

The abstract on record is too brief for a reliable plain-language summary, so none has been generated.

Abstract

National Health and Medical Research Council of Australia and Bill and Melinda Gates Foundation.

Research topics

  • Malaria Research and Control
  • Drug-Induced Ocular Toxicity
  • Morinda citrifolia extract uses

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher siteRecord on OpenAlex

DOI: 10.1016/s1473-3099(25)00729-7

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

Sign in to join the discussion

New to MARATTO™? Create a free account.